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Cardiac injury induces myocardial expression of the thyroid hormone inactivating type 3 deiodi-
nase (D3), which in turn dampens local thyroid hormone signaling. Here, we show that the D3
gene (Dio3) is a tissue-specific imprinted gene in the heart, and thus, heterozygous D3 knockout
(HtzD3KO) mice constitute a model of cardiac D3 inactivation in an otherwise systemically euthy-
roid animal. HtzD3KO newborns have normal hearts but later develop restrictive cardiomyopathy
due to cardiac-specific increase in thyroid hormone signaling, including myocardial fibrosis, im-
pairedmyocardial contractility, and diastolic dysfunction. Inwild-type littermates, treatmentwith
isoproterenol-induced myocardial D3 activity and an increase in the left ventricular volumes,
typical of cardiac remodeling and dilatation. Remarkably, isoproterenol-treated HtzD3KO mice
experienced a further decrease in left ventricular volumes with worsening of the diastolic dys-
function and the restrictive cardiomyopathy, resulting in congestive heart failure and increased
mortality. These findings reveal crucial roles forDio3 in heart function and remodeling,whichmay
have pathophysiologic implications for human restrictive cardiomyopathy. (Molecular
Endocrinology 26: 809–818, 2012)
The current model of thyroid hormone action holdsthat deiodinases mediate intracellular changes in thy-
roid hormone activation or deactivation that are key to
many metabolic effects, regardless of plasma hormone
concentrations. These enzymes, such as the type 2 deio-
dinase (D2), accelerate activation of T4 to T3 and increase
local thyroid hormone action. In contrast, the type 3 de-
iodinase (D3) irreversibly inactivates both T4 and T3,
thereby dampening thyroid hormone action and creating
localized hypothyroidism on a cell-specific basis. Impor-
tantly, this local control of thyroid hormone action occurs
without substantial changes in circulating levels of T4 and
T3 and thus cannot be predicted by measurements of se-
rum T4 and/or T3 levels (1).
There is widespread D3 expression in vertebrates dur-
ing development, and D3 levels are inversely coordinated
with D2, so that thyroid hormone signaling in a given
tissue can be controlled according to the developmental
stage (2). For example, in the 3-d period during which
brown adipose tissue is formed (E16.5–E18.5), there is a
simultaneous decrease in D3 and increase in D2, aug-
menting local T3 concentration and thyroid hormone sig-
naling (3). After birth, D3 expression subsides in most
tissues to background levels, and D3 activity remains
largely restricted to brain and skin. However, disease sig-
nals in the adult human and other mammals can reacti-
vate D3 expression in a number of tissues (4, 5). In rat
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myocardium, for example, right ventricular (RV) hyper-
trophy caused by pulmonary arterial hypertension results
in an approximately 5-fold induction in local D3 activity,
which in turn decreases sarcoplasmic reticulum Ca2-AT-
Pase type 2 (SERCA-2)a and -myosin heavy chain
(MHC) gene expression, and increase levels of -MHC
mRNA, a pattern that is typical of the hypothyroid heart
(6). In fact, D3 induction in this animal model is linked to
RV hypoxia and accumulation of hypoxia inducible fac-
tor-1, creating an anatomically specific reduction in lo-
cal T3 content and action (7). Myocardial infarction in
rats (8) and mice (9) also leads to a potent chamber-
specific induction of D3. In the latter model, in vivomea-
surement of thyroid hormone-dependent transcription
activity in cardiomyocytes using a luciferase reporter as-
say revealed a marked decrease post-myocardial infarc-
tion, which was associated with a 50% decrease in left
ventricle (LV) T3 concentration (9).
The paradigm emerging from these studies is that the
hypoxic myocardium banks on the D3-mediated decrease
in T3 signaling to ultimately slow down the rate of oxygen
consumption (VO2); it is not clear yet whether local hy-
pothyroidism is necessary for myocardium remodeling.
At the same time, the link between hypoxia and D3 in-
duction has also been observed in cultures of hepatocytes
and neurons (7, 10), suggesting that these D3-mediated
changes in local thyroid hormone action constitute a
broad adaptive response. In fact, a number of other disease
and tissue injurymodels exhibit similar D3 reactivation and
local down-regulationof thyroidhormone signaling, suchas
cerebral hypoxia, inflammation or oxidative stress, nerve
injury, and liver resection-regeneration, suggesting that D3
induction in the heart is part of the hypoxia inducible factor-
1-orchestrated response generally seen in tissue injury,
hypoxia, and/or ischemia (5).
The D3 gene (Dio3) is located in the delta-like 1
homolog-Dio3 domain positioned on distal mouse chro-
mosome 12 and human chromosome 14 (11). The do-
main contains three paternally imprinting protein-encod-
ing genes that share common regulatory elements, delta-
like 1 homolog, retrotransponson-like gene 1, and Dio3,
i.e. only the paternally inherited allele is expressed. This is
explained based on the differences between the chromatin
structures such as degree of DNA methylation and post-
translational modifications to core histone proteins. In
mice,Dio3 imprinting does not happen in all tissues, and
even where it happens is not complete, with the paternal
allele contributing with approximately 84% of expres-
sion in the embryo and 50–60% in the placenta (12).
Here, we show that Dio3 imprinting takes place in the
mouse heart but not in the brain, and
thus, the heterozygous D3 knockout
(HtzD3KO) mice lends itself as a
model of cardiac-specific Dio3 inacti-
vation. Strikingly, the myocardium of
1-d-old HtzD3KO pups is normal but,
as a result of the lifelong cardiac in-
crease in thyroid hormone signaling,
4-month-old animals exhibit a unique
phenotype of restrictive cardiomyopa-
thy that includes myocardial fibrosis,
impaired myocardial contractility, and
diastolic dysfunction. A sympathetic
overdrive with a 10-d treatment with
isoproterenol (ISO) worsened this phe-
notype, with further reductions in the
LV volumes and accentuation of the
diastolic dysfunction, which caused
congestive heart failure and doubled
the mortality rate. In sharp contrast,
wild-type (WT) siblings were able to
potently reactivatemyocardial D3, and
cardiac remodeling took place with LV
dilatation. Given that D3 reactivation
is present in critically ill patients with
compromised myocardial perfusion
(4), the present findings may have
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FIG. 1. HtzD3KO mice are systemically euthyroid. Cerebral cortex D3 activity (A), thyrotropin,
T3, and T4 serum levels (B), body weight (data entries from both groups are superimposed)
(C), daily caloric intake (D), VO2 measure during 48-h period (E), 24-h RQ (F), and EE (total
daily EE) (G) in WT and HtzD3KO mice. Shaded areas indicate night time. A–G, Data are
expressed as mean  SEM of three to five animals in each group.
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pathophysiologic implications for human restrictive
cardiomyopathy.
Results
The HtzD3KO mouse is euthyroid
TheWT heart exhibits minimal D3 activity (0.4 fmol
T3/minmg protein), about 40-fold less than the D3 activ-
ity found in the brain (Fig. 1A, see also Fig. 3A below).
The HtzD3KO mouse has normal brain D3 activity (Fig.
1A) but lacks cardiac D3 activity (0.15 fmol T3/minmg
protein), indicating that the heart is one of the tissues in
which Dio3 is imprinted. Thus, the HtzD3KO mouse
constitutes a suitable model of cardiac-specific Dio3 in-
activation in an otherwise systemically euthyroid mouse.
Accordingly, HtzD3KOmice exhibit normal serum levels
of thyrotropin, T4 and T3 (Fig. 1B), and growth rates (Fig.
1C) as compared with the WT siblings. In addition,
HtzD3KO mice exhibit normal 24-h caloric intake (Fig.
1D), daily VO2 (Fig. 1E), respiratory quotient (RQ) (Fig.
1F), and energy expenditure (EE) (Fig. 1G), parameters
that are strongly affected by thyroid status and serum
thyroid hormone levels.
The HtzD3KO heart exhibits fibrosis, decreased
maximal force, and diastolic dysfunction
The neonatal (postnatal day 1) HtzD3KO heart is his-
tologically normal (Fig. 2, A and B) with similar expres-
sion pattern of key genes as compared with WT controls
(Supplemental Table 1, published on The Endocrine So-
ceity’s Journals Online web site at http://mend.endojournals.
org). However, in 4-month-old HtzD3KO mice, the LV
exhibits a typical gene expression pattern of increased
thyroid hormone signaling (13, 14), i.e. an approximately
30% increase in the -MHC/-MHC mRNA ratio (Sup-
plemental Table 1). The HtzD3KO LV also exhibits ap-
proximately 35% decrease in the SERCA-2/phospholam-
ban (PLN) mRNA ratio as well as an approximately 30%
increase in uncoupling protein-2 mRNA (Supplemental
Table 1). The expression of other met-
abolically relevant genes, such as perox-
isome proliferator-activated receptor ,
glucose transporter-4, glutathione peroxi-
dase-1, was not altered in the HtzD3KO
hearts (Supplemental Table 1).
To study the cardiac impact of life-
long localized myocardial increase in
thyroid hormone signaling, we first
looked at structural parameters. Histo-
logic examination of the HtzD3KO
heart revealed that the LVmyocardium
(Fig. 2, C and D) and cardiac septum
(Fig. 2, E and F) had substantial inter-
stitial fibrosis, a feature previously re-
ported in the thyrotoxic heart (15, 16).
This coincides with an approximately
12-fold increase in type I collagen
mRNA levels observed in the
HtzD3KO LV (Supplemental Table 1).
HtzD3KO hearts exhibited signs of
cardiac hypertrophy (8.8  0.51 vs.
7.2  0.27 mg/mm heart weight/tibial
length; n  8; P  0.04) associated
with a thicker LV wall (Fig. 2, G–I).
The impact of myocardial fibrosis
was documented in preparations of
HtzD3KO skinned papillary muscles,
which exhibited about 30% decrease
in calcium-activated maximal force
(46  1.2 vs. 32  0.88 kN/m2; n 
14; P  0.01), with a similar stiffness
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FIG. 2. Effect of life-long D3 inactivation in the heart. Representative sections of newborn LV
myocardium (A and B), adult (4 month old) LV myocardium (C and D), adult cardiac septum (E
and F), and heart cross-sectional analyses (G and H) of adult WT and HtzD3KO mice obtained
after 20 mM KCl was infused for 10 min. Scale bars, 20 m. Relative wall thickness (RWT) is
the LV/RV wall ratio (I), arterial elastance (Ea) (J), end-diastolic pressure (EDP) (K), isovolumic
relaxation constant () (L) at baseline and during acute ISO infusion at the indicated doses. In
A–L, data are expressed as mean  SEM of three to four animals in each group; *, P  0.01
vs. WT siblings.
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(ranging from 2 to 18 kN/m2) during a 10–40%
stretch ramp and myofilament calcium sensitivity
(pCa50  5.71  0.01 vs. 5.68  0.01).
HtzD3KO LV exhibited impaired diastolic function as
assessed by echocardiography (Table 1). Importantly LV
volumes were decreased, as was the E/A (early and late/
atrial) ratio, an index of diastolic chamber filling. Cardiac
expression of brain natriuretic peptide mRNA levels, a
sensitive marker of congestive heart failure, was not ele-
vated in HtzD3KO LV (Supplemental Table 1).
Subsequent studies of pressure-volume (PV) relation-
ships at baseline and during acute infusion of increasing
doses of ISO indicate that the development of LV hyper-
trophy and fibrosis is not due to an increase in cardiovas-
cular afterload given that arterial elastance was similar in
both groups (Fig. 2J). However, the LV diastolic function
assessed by the end-diastolic pressure (Fig. 2K) and by
isovolumic relaxation constant () (Fig. 2L) was increased
in the HtzD3KO compare with WT at the baseline. Al-
though resting parameters of contractile function and
performance were similar between groups, the -adren-
ergic contractile reserve was suppressed (Supplemental
Fig. 1, published on The Endocrine Society’s Journals
Online web site at http://mend.endojournals.org), consis-
tent with the findings in isolated muscle strips.
ISO-induced LV D3 expression promotes cardiac-
specific hypothyroidism
We next extended our analysis and tested the conse-
quences of absence of cardiac D3 during adrenergic over-
drive, a recognized model of endocardial injury and dia-
stolic dysfunction that can lead to heart failure (17).
Accordingly, only in WT animals did chronic treatment
with ISO stimulated D3 reactivation (2.5-fold induc-
tion) (Fig. 3A) given that induction of Dio3 is part of the
changes in cardiac gene expression associated with ven-
TABLE 1. Ecochardiographic and Doppler studies of WT and HtzD3KO hearts
Parameter WT HtzD3KO
Echocardiographic studies
Heart rate (bpm) 480.6  13 474.9 8.5
LV volume, diastole (l) 67.8 5.6 48.3 4.0a
LV volume, systole (l) 27.7 3.1 16.2 2.7a
Fractional shortening (%) 31.1 2.1 41.5 3.2a
Ejection fraction (%) 58.9 2.9 70.7 3.4a
Cardiac output (ml/min) 17.3 2.1 14.8 1.1a
Endocardial stroke volume (l) 35.9 4.0 31.4 2.1a
Doppler studies
E/A ratio 1.400.2 1.100.1b
AV peak gradient (mm Hg) 2.700.5 1.700.2a
Ejection time (msec) 47.5 2.7 46.5 1.2
Isovolumic contraction time (msec) 23.0 1.6 25.0 1.8
Isovolumic relaxation time (msec) 21.5 1.0 22.5 2.4
AV peak velocity (mm/sec) 807.0  87 645.0 26b
MV deceleration time (msec) 20.0 5.0 21.0 2.0
Aortic acceleration time (msec) 16.0 2.9 15.5 0.9
Values are the mean  SEM of 4–20 animals per group.
a P  0.01 vs. WT, t test.
b P  0.05 vs. WT, t rest.
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FIG. 3. Effects of treatment with ISO on myocardial D3 activity, body weight, and survival of WT and HtzD3KO mice. A, LV D3 activity after ISO
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daily, and variances (BW) are shown. Data are expressed as mean  SEM of 5–10 animals in each group; *, P  0.01 vs. WT-ISO and **, P 
0.001 vs. HtzD3KO-SAL. C, Kaplan-Mayer survival plot during ISO treatment. Data are expressed as mean  SEM of five to eight animals in each
group (data entries from WT-SAL and HtzD3KO-SAL are superimposed); P  0.01 vs. WT-ISO.
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tricular hypertrophy (6, 7). In all animals, RV D3 activity
was undetectable (Supplemental Fig. 2).
ISO administration minimally affected body weight in
WT siblings (P  0.05) (Fig. 3B), but resulted in an ap-
proximately 20% cumulative mortality rate in this group
as shown by the Kaplan-Meyer survival curve (Fig. 3C).
However, in the HtzD3KO animals, ISO treatment was
associated with significant drop in body weight that was
evident as early as d 5, reaching approximately 15% at
the end of the 10-d treatment period (Fig. 3B). The cumu-
lative mortality rate was doubled in the HtzD3KO ani-
mals, reaching about 40% (Fig. 3C). In both groups of
animals, death was sudden and associated with signs of
pulmonary edema and LV insufficiency.
The potent cardiac induction of D3 in the WT animals
triggered by ISO (Fig. 3A) is likely to reduce local thyroid
hormone signaling provided by plasma T3. This is in con-
trast with the situation in the HtzD3KO heart, to which
plasma T3 has unopposed access given its lack of D3. To
test this scenario, we analyzed the isovolumic ventricular
contraction time (IVCT), a T3-sensitive echocardio-
graphic parameter, in both groups of animals before/after
treatment with ISO (18). In theWT siblings, which devel-
oped the potent cardiac D3 induction (Fig. 3A), treatment
with ISO caused an approximately 50% prolongation in
the IVCT (Fig. 4A), a finding that is compatible with the
D3-mediated reduction in thyroid hormone signaling.
However, besides T3, there are other potential regulators
of this parameter, particularly in the context of ISO-in-
duced cardiac hypertrophy. Thus, the T3 dependency of
these changes was established in the HtzD3KO animals,
in which there was no induction of D3, and no ISO-
induced changes in IVCT were observed (Fig. 4A). At the
same time, the isovolumic ventricular relaxation time re-
mained stable in all groups during treatment with ISO
(Fig. 4B).
The changes in the myocardial -MHC/-MHC ratio
correlated only in part with the observed D3-induced
modifications in thyroid hormone signaling, given that in
the failing heart, there is a natural shift in MHC isoform
content from -MHC to -MHC and a decrease in the
SERCA-2/PLN ratio (13). Thus, in ISO-treated WT sib-
lings, induction of D3 correlated well with a reduction in
-MHCmRNA (1.02 0.02 vs. 0.81 0.02, P 0.001;
n  3) and elevation in -MHC (1.05  0.02 vs. 1.23 
0.02, P  0.003; n  3). Furthermore, there was no sig-
nificant decrease in -MHC mRNA
(1.23 0.02 vs. 1.13 0.005, not sig-
nificant; n  3) in ISO-treated
HtzD3KO animals. Nevertheless, the
-MHC/-MHC ratio was reduced as
in the WT siblings largely due to a
marked elevation in -MHC mRNA
(0.98 0.02 vs. 0.64 0.64,P 0.05;
n  3). SERCA-2 mRNA levels were
not affected by treatment with ISO but
SERCA-2/PLN ratio was, dropping
about 30% only in the ISO-treated
HtzD3KO animals (1.3  0.03 vs.
0.96  0.001, P  0.0003; n  3).
Changes in thyroid hormone signaling
and gene expression profiles were
chamber specific, given that -MHC/
-MHC and SERCA-2/PLN ratios re-
mained unaffected in the RV of ISO-
treated animals (Supplemental Fig. 2).
InWT animals, 10-d treatment with
ISO reduced serumT4 (T4, 45 2.1 vs.
23  1.7 ng/ml; n  3; P  0.001 by
ANOVA) and increase serum T3 (T3,
1.06 0.04 vs. 1.35 0.02 ng/ml; n
5; P  0.001), which reflects acceler-
ated D2-mediated conversion of T4 to
T3, a cAMP-dependent pathway. In the
HtzD3KO animals, the interpretation
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of the thyroid function tests is complicated by the weight
loss and illness exhibited by these animals (Fig. 3, B and
C). In these animals, both serumT4 (49 8.3 vs. 16 2.7
ng/ml; n  3; P  0.001 by ANOVA) and serum T3
(0.90  0.04 vs. 0.77  0.04 ng/ml; n  5; P  0.05 by
ANOVA) were reduced by treatment with ISO.
The HtzD3KO mouse develops accentuation of
restrictive cardiomyopathy during ISO-induced
cardiac hypertrophy
To document this further, we used echocardiography
and Doppler studies and examined the hearts of the sur-
viving animals at the end of the 10-d ISO treatment, fo-
cusing on the LV volumes during the cardiac cycle (Fig.
4). In the WT siblings, the aortic valve peak gradient,
which reflects the pressure gradient between the LV and
the aorta, was not affected by treatmentwith ISO in either
group, but this parameter was significantly greater in the
WTsiblings as comparedwith theHtzD3KOmice (Fig. 4C).
In addition, at baseline, the end-diastolic and end-sys-
tolic LV volumes were decreased in the HtzD3KO ani-
mals compare with WT siblings, indicating a decrease in
LV dimensions (Fig. 4D). In the WT siblings, treatment
with ISO increased the end-diastolic and end-systolic LV
volumes (Fig. 4D), indicating cardiac remodeling and dil-
atation. In sharp contrast, in the htzD3KO animals, treat-
ment with ISO decreased both the end-diastolic and the
end-systolic ventricular volumes (Fig. 4D), indicating an
accentuation of the restrictive cardiomyopathy.
The necropsy of these animals revealed that in both
groups treatment with ISO increased heart weight, albeit
more pronounced in the HtzD3KO animals (35 vs.
50% after correction for tibial length) (Supplemental
Fig. 3A). At the same time, only in the HtzD3KO animals
did ISO treatment result in a heavier lung (Supplemental
Fig. 3B) and an approximately 3.5-fold increase in brain
natriuretic peptide mRNA levels (Supplemental Fig. 3C),
consistent with congestive heart failure. On the other
hand, ventricular atrial natriuretic peptide mRNA levels
were unaffected (Supplemental Fig. 3D), and liver weight
remained similar in all groups, suggesting no or minimal
involvement of the RV function (Supplemental Fig. 3E).
There was clear evidence of myocardial fibrosis in the
ISO-treated WT siblings (Fig. 4E), whereas the fibrosis
observed at baseline in the HtzD3KO animals did seem to
intensify further by ISO (Fig. 2, D and F, vs. Fig. 4F).
These data were largely confirmed by measuring myocar-
dium collagen I mRNA levels by RT-PCR (Fig. 4G). In all
groups and times, induction of type I collagen expression
was minimal in the RV (Fig. 4H).
Analysis of the skinned cardiac fiber and gene
expression profile explain diastolic dysfunction in
HtzD3 heart
To understand the nature of the diastolic dysfunction
in the ISO-treated HtzD3KO hearts, skinned cardiac fi-
bers were studied in situ. Treatment with ISO decreased
about 30% the calcium-activatedmaximal force (Fig. 5A)
in the WT fibers, reaching the levels seen in the
HtzD3KO. At the same time, both WT and HtzD3KO
siblings exhibited a similar increase in basal force as a
function of fiber stretch (stiffness), which ranged from
about 2 to 50 kN/m2 (Fig. 5B). The assessment of myo-
filament calcium sensitivity revealed a leftward shift in the
ISO-treated HtzD3KO animals, a typical alteration ob-
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served during hypertrophic cardiomyopathy (Fig. 5C)
(19).
Furthermore, the analyses of key myocardium mRNA
also indicated a contrasting metabolic profile between
WT and HtzD3KO animals after treatment with ISO.
Although ISO treatment increased by 3- to 4-fold uncou-
pling protein-2 and GPX-1 (response to oxidative stress),
Glut-4 (glycolysis), and PPAR (-oxidation) mRNA lev-
els in WT animals, all of these mRNA were decreased by
3- to 4-fold in the HtzD3KO animals, suggesting a mal-
adaptive process (Supplemental Fig. 4).
Discussion
LV hypertrophy is widespread, affecting more than 15%
of the United States adult population. It is progressive,
and its prevalence increases with age, affecting more than
one-third of individuals over the age of 70 (20). Although
we do not understand fully the molecular underpinnings
of LV hypertrophy, it is remarkable that D3-mediated
cardiac-specific hypothyroidism rises as a common de-
nominator and important feature in cardiac remodeling.
In addition, other mechanisms to decrease myocardial
thyroid hormone signaling that result in a hypothyroid-
like mRNA phenotype have been reported during cardiac
remodeling, including a decrease in thyroid hormone re-
ceptor expression in two rat models of cardiac hypertro-
phy [voluntary wheel running for 10 wk in adult male
Wistar rats or ascending aortic constriction (pressure gra-
dient 75 mm Hg) for 4 wk] (21). The most striking
finding in the present study, however, was the contrasting
phenotype caused by the absence of myocardial D3 dur-
ing adrenergic overdrive (Fig. 4D). Although ISO-treated
WT animals develop an enlarged LV, the HtzD3KO ani-
mals responded by reducing their LV volumes even fur-
ther, worsening the restrictive cardiomyopathy and dia-
stolic dysfunction, leading to congestive heart failure
(Supplemental Fig. 3, B and C) and increased mortality
(Fig. 3C). Thus, HtzD3KO animals have limited ability of
cardiac remodeling during adrenergic overdrive likely as a
result of the heart’s inability to create localized hypothy-
roidism. Of note, an additional contributing factor to the
poor performance exhibited by the HtzD3KO heart is
likely to be the baseline cardiac fibrosis already present
before ISO treatment was initiated, which is the result of
long-term D3 deficiency in the HtzD3KO heart. Collec-
tively, these data constitute strong objective evidence that
myocardial D3 reactivation during adrenergic overdrive
is adaptive, the absence of which leads to pathological
myocardium remodeling.
The presence of myocardium fibrosis (Fig. 2, D and F)
with decreased calcium-activated maximal force, LV hy-
pertrophy (Fig. 2, G–I), and diastolic dysfunction (Fig. 2,
K and L) underlie a state of restrictive cardiomyopathy in
the HtzD3KO mice, revealing an critical role played by
D3 in the normal myocardium. The implication of these
findings is that the very low level of D3 activity present in
the normal heart provides a physiological state of local-
ized hypothyroidism, which the present data indicate is
physiologically relevant. Although LV T3 concentrations
were notmeasured in the present experiments, the relative
increase in thyroid hormone signaling is supported by the
typical gene expression profile of the HtzD3KO myocar-
dium (Supplemental Table 1) (13), including elevations in
the -MHC/-MHC and SERCA-2/PLN ratios, despite
normal serum T3. Although of course we cannot discard
that the fibrosis per se initiated such changes in gene ex-
pression, the consistent modification of four different T3-
responsive genes points toward enhanced T3 signaling.
Alternatively, it is conceivable that D3 expression in the
“normal” myocardium reflects a small number of cardi-
omyocytes that are injured or damaged at any given time
and are undergoing a remodeling process that requires
induction ofD3. These areaswould thus account forwhat
seems like global low level D3 expression.
Of note, LV afterload was similar between theWT and
HtzD3KO animals (Fig. 2J), strongly suggesting that re-
active hypertrophy is not operative in the D3KO mice.
Thus, it is likely that this relative increase in thyroid hor-
mone signaling underlies the myocardial fibrosis in these
animals, given previous reports of myocardial fibrosis in
thyrotoxic patients (15, 16). In turn, the fibrosis explains
the decreased performance of the HtzD3KO skinned pap-
illary muscle preparations (Fig. 5), leading to the pheno-
type of restrictive cardiomyopathy. Previous attempts to
promote cardiac-specific increase in thyroid hormone sig-
naling by way of transgenic myocardial overexpression of
D2 resulted in the expected increase in adrenergic signal-
ing and T3-dependent gene expression profile such as ob-
served in the present studies, but myocardial fibrosis was
not investigated in those studies (22, 23).
The inducible cardiac D3 activity reported in this study
(observed in the ISO-treated WT animals) reached about
1 fmol/mg protein/min, a figure that is similar to all other
reports of inducible cardiac D3 activity in mice and rats
(6, 7, 9). As reported, at these levels of D3 activity, there
is reduction of tissue T3 levels and T3-dependent tran-
scription of 40–50% (7, 9), indicating that similar mech-
anisms are taking place in the ISO-treated animals that
exhibited D3 induction. Thus, it is not surprising that in
ourmodel of ISO-induced cardiac hypertrophy, there was
echocardiographic evidence of myocardium hypothy-
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roidism such as approximately 60% prolongation of the
IVCT (Fig. 4A). Of note, the IVCT is a reliable T3-sensi-
tive biological parameter that has been widely used in the
clinical setting to adjust the replacement dose of levothy-
roxine T4 when serum thyrotropin cannot be used, such
as in patients with secondary hypothyroidism (24).
In conclusion, the heart’s ability to reactivate D3 in
response to injury is a critical component of a successful
remodeling process. In its absence, there is restrictive car-
diomyopathy that is further accentuated in response to an
adrenergic overdrive. Although we do not understand the
molecular underpinnings of these adaptive mechanisms,
it is conceivable that a reduction in thyroid hormone sig-
naling establishes an adaptive transcriptional footprint
that is favorable to cardiac remodeling. It is fascinating
that D3-mediated hypothyroidism in response to illness is
not unique to the heart, being observed in other models of
tissue injury and healing, including cerebral ischemia,
liver resection, and nerve injury, suggesting that D3 reac-
tivation is part of a much broader adaptive network that
is set in motion in response to illness.
Materials and Methods
Mice
All studies were performed according to a protocol approved
by the Animal Care and Use Committee of University of Miami
in compliance with National Institutes of Health standards. All
experiments were conducted in newborns (P1) or 4-month-old
129/Sv/C57 Black/6J male mice. All mice were housed under a
12-h light, 12-h dark cycle at 22 1 C, kept on a chow diet and
water ad libitum. Mice with targeted disruption of the Dio3
gene (D3KO) were previously described (25). A colony of ani-
mals heterozygous for theD3 inactivatingmutation (HtzD3KO)
and WT littermates derived from a male HtzD3KO mouse was
studied.
Indirect calorimetry
Indirect calorimetry (VO2, RQ, and EE) was performed in a
Comprehensive Lab Animal Monitoring System (Columbus In-
struments, Columbus, OH), a computer-controlled open circuit
calorimetry system, as described (26).
Treatment with ISO
This was done by sc injections of D-L ISO [100 mg/Kg body
weight (BW)/d; Sigma, St. Louis, MO] or 0.9% saline for 10 d.
Transthoracic echocardiography and Doppler
studies
Cardiac function was monitored by Vevo 770 imaging sys-
tem (VisualSonic, Inc., Toronto, Canada) at baseline and at the
end of the treatment period. Images were recorded under anes-
thesia with isoflurane inhalation (1%) at heart rates above 400
bpm and body temperatures of 37  1 C. Heart sonographic
structural parameters were determined using the M-mode and
two-dimensional images. Doppler echocardiographic images of
mitral and aortic valves were recorded and calculated
accordingly.
PV loop
Hemodynamic evaluation using a conductance manometry
catheter was done while PV loops were recorded. Under general
anesthesia (1% isoflurane) mice were intubated, and the inter-
nal carotid was canulated so that a PV loop catheter (SPR 839;
Millar Instruments, TX) was passed to the LV to allow steady
state occlusion parameters to be recorded at baseline and also
with three doses of iv ISO infusion (10, 20, and 40 ng/kg BW/
min for 5 min).
Euthanasia and serum levels of thyrotropin, T4,
and T3
At the end of the experimental periods and procedures, mice
were euthanized by CO2 asphyxiation. Blood was collected and
serum levels of thyrotropin, T4, and T3 measured using a MIL-
LIPLEX rat thyroid hormone panel kit as described by the man-
ufacturer (Millipore Corp., Billerica,MA) and read on a BioPlex
(Bio-Rad, Hercules, CA). Heart, lung, and liver were harvested,
and organ weights were expressed as a function of the tibial
length.
Histological studies
Hearts fixed in 4% paraformaldehyde and placed in a 30%
sucrose solution prepared in 0.1 M phosphate buffer. Then sam-
ples were snap frozen in liquid nitrogen and stored at 	80 C
until further processing. Hearts were then sliced transversely
(2 mm) at papillary level, and staining was with hematoxilin
and eosin as well as Masson’s trichrome.
mRNA analysis
Total heart RNA was extracted using the RNeasy kit (QIA-
GEN Sciences, Valencia, CA), and 2.5 g of total RNA were
reverse transcribed using High Capacity cDNA Reverse Tran-
scription kit (Applied Biosystem, Foster City, CA). Abundance
of mRNA molecules of interest was measured by RT-quantita-
tive PCR (Bio-Rad iCycler iQ Real-Time PCR Detection Sys-
tem). In all assays, amplification efficiency was more than 90%
and r2 more than 0.95. Results are expressed as ratios of mRNA
of interest/cyclophilin A mRNA.
D3 assay using ultra performance liquid
chromatography
D3 activity was measured in the hearts and brain of all ani-
mals. Frozen tissue was processed with a Tissue Tearor (BioSpec
Products, Bartlesville, OK) and homogenized in 10 mM dithio-
threitol and 0.25 M sucrose. D3 activity was measured as previ-
ously described (10) using 150 g of protein homogenate incu-
bated at 37 C with 0.1 or 100 nM 3,5,[125I]3
-triiodothyronine
(PerkinElmer Life and Analytical Sciences, Inc., Waltham, MA)
and 30 mM dithiothreitol. Reactions were stopped by addition
of methanol and the products of deiodination separated by ultra
performance liquid chromatography (ACQUITY; Waters
Corp., Milford, MA) and quantified by a flow scintillation an-
alyzer (PerkinElmer, Shelton, CT).
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Mouse skinned cardiac fiber preparation and
measurement of the Ca2 sensitivity of force
development, maximal force, and resistance to
stretch
Skinned papillary muscles were prepared from the LV of
freshly obtainedWT or HtzD3KOmouse hearts following stan-
dard protocols of the laboratory (27). Strips of LV papillary
muscle were extracted and incubated in a pCa 8.0 solution con-
taining 1% Triton X-100 and 50% glycerol at 4 C for approx-
imately 4–6 h. Fibers were then transferred to the same solution
without Triton X-100 and stored at	20 C.Mouse muscle fiber
bundles with a diameter varying between 65 and 139 m, and
approximately 1.3 mm of length were attached to tweezer clips
connected to a force transducer. To ensure complete membrane
removal and complete access to themyofilament, the fibers were
treated with pCa 8.0 containing 1% Triton X-100 for 30 min
before the beginning of the experiment. To remove the excess
TritonX-100 from the fibers, extensive washing was carried out
with pCa 8.0, and then the functional parameters were evalu-
ated. To determine the Ca2 sensitivity of force development,
the fibers were gradually exposed to solutions of increasing
Ca2 concentration from pCa 8.0 to 4.0. Data were analyzed
using the following equation: % change in force  100 
[Ca2]n/([Ca2]n  [Ca250]
n), where [Ca250] is the free
[Ca2] that produces 50% force and n is theHill coefficient. The
maximal force in kN/m2 developed by the fibers was evaluated
by incubating the fiber in pCa 4.0 solution. For the stretch-force
relationship measurements, the slack length from the fiber was
determined by releasing and stretching until it begins generating
tension. We set this point as zero for both the passive force and
starting length. After this, the fiber was consecutively stretched
10% of its original length, and the passive force in kN/m2 was
recorded. These experiments were carried out in relaxing solu-
tion (pCa 8.0).
Statistical analysis
All data were analyzed using PRISM software (GraphPad
Software, Inc., San Diego, CA) and expressed as mean  SEM.
The Student’s t test was used to compare differences between
two groups. One-way ANOVAwas used to compare more than
two groups, followed by the Student-Newman-Keuls post hoc
test to detect differences between groups.
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